Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis

Maria Luisa Blanchi, R. Cimaz, E. Galbiati, F. Corona, R. Cherubini, M. Bardare

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Thirty-two children affected by juvenile rheumatoid arthritis (JRA) were studied with serial measurements of bone mass for an average of 18 months, to evaluate the effects of long-term methotrexate (MTX) treatment on bone. Bone mineral density (BMD) was measured on lumbar spine and total body. During MTX therapy some increase in BMD was observed, though this was smaller than in a control group of healthy children. Axial (spine and trunk) and appendicular (upper and lower limbs) BMD showed similar increases. BMD, either as an absolute value or as a percent variation from baseline, did not correlate with either MTX dose or length of therapy. In children treated also with corticosteroids, these drugs negatively influ enced bone mass increase. The main determinant of absolute spine BMD value appeared to be weight, while height and lean mass seemed to be the determinants of total body BMD. Pubertal stage and disease activity significantly influenced the yearly change in BMD. In conclusion, our data suggest that long-term, low-dose therapy with MTX does not induce osteopenia in children with JRA.

Original languageEnglish
Pages (from-to)20-25
Number of pages6
JournalOsteoporosis International
Volume10
Issue number1
DOIs
Publication statusPublished - 1999

Fingerprint

Juvenile Arthritis
Methotrexate
Bone Density
Bone and Bones
Spine
Therapeutics
Metabolic Bone Diseases
Lower Extremity
Adrenal Cortex Hormones
Weights and Measures
Control Groups
Pharmaceutical Preparations

Keywords

  • Bone mass
  • Bone mineral density
  • Children
  • Methotrexate
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis. / Blanchi, Maria Luisa; Cimaz, R.; Galbiati, E.; Corona, F.; Cherubini, R.; Bardare, M.

In: Osteoporosis International, Vol. 10, No. 1, 1999, p. 20-25.

Research output: Contribution to journalArticle

Blanchi, Maria Luisa ; Cimaz, R. ; Galbiati, E. ; Corona, F. ; Cherubini, R. ; Bardare, M. / Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis. In: Osteoporosis International. 1999 ; Vol. 10, No. 1. pp. 20-25.
@article{1ba955ec71a14f1a844f36d99cbf70fe,
title = "Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis",
abstract = "Thirty-two children affected by juvenile rheumatoid arthritis (JRA) were studied with serial measurements of bone mass for an average of 18 months, to evaluate the effects of long-term methotrexate (MTX) treatment on bone. Bone mineral density (BMD) was measured on lumbar spine and total body. During MTX therapy some increase in BMD was observed, though this was smaller than in a control group of healthy children. Axial (spine and trunk) and appendicular (upper and lower limbs) BMD showed similar increases. BMD, either as an absolute value or as a percent variation from baseline, did not correlate with either MTX dose or length of therapy. In children treated also with corticosteroids, these drugs negatively influ enced bone mass increase. The main determinant of absolute spine BMD value appeared to be weight, while height and lean mass seemed to be the determinants of total body BMD. Pubertal stage and disease activity significantly influenced the yearly change in BMD. In conclusion, our data suggest that long-term, low-dose therapy with MTX does not induce osteopenia in children with JRA.",
keywords = "Bone mass, Bone mineral density, Children, Methotrexate, Rheumatoid arthritis",
author = "Blanchi, {Maria Luisa} and R. Cimaz and E. Galbiati and F. Corona and R. Cherubini and M. Bardare",
year = "1999",
doi = "10.1007/s001980050189",
language = "English",
volume = "10",
pages = "20--25",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "1",

}

TY - JOUR

T1 - Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis

AU - Blanchi, Maria Luisa

AU - Cimaz, R.

AU - Galbiati, E.

AU - Corona, F.

AU - Cherubini, R.

AU - Bardare, M.

PY - 1999

Y1 - 1999

N2 - Thirty-two children affected by juvenile rheumatoid arthritis (JRA) were studied with serial measurements of bone mass for an average of 18 months, to evaluate the effects of long-term methotrexate (MTX) treatment on bone. Bone mineral density (BMD) was measured on lumbar spine and total body. During MTX therapy some increase in BMD was observed, though this was smaller than in a control group of healthy children. Axial (spine and trunk) and appendicular (upper and lower limbs) BMD showed similar increases. BMD, either as an absolute value or as a percent variation from baseline, did not correlate with either MTX dose or length of therapy. In children treated also with corticosteroids, these drugs negatively influ enced bone mass increase. The main determinant of absolute spine BMD value appeared to be weight, while height and lean mass seemed to be the determinants of total body BMD. Pubertal stage and disease activity significantly influenced the yearly change in BMD. In conclusion, our data suggest that long-term, low-dose therapy with MTX does not induce osteopenia in children with JRA.

AB - Thirty-two children affected by juvenile rheumatoid arthritis (JRA) were studied with serial measurements of bone mass for an average of 18 months, to evaluate the effects of long-term methotrexate (MTX) treatment on bone. Bone mineral density (BMD) was measured on lumbar spine and total body. During MTX therapy some increase in BMD was observed, though this was smaller than in a control group of healthy children. Axial (spine and trunk) and appendicular (upper and lower limbs) BMD showed similar increases. BMD, either as an absolute value or as a percent variation from baseline, did not correlate with either MTX dose or length of therapy. In children treated also with corticosteroids, these drugs negatively influ enced bone mass increase. The main determinant of absolute spine BMD value appeared to be weight, while height and lean mass seemed to be the determinants of total body BMD. Pubertal stage and disease activity significantly influenced the yearly change in BMD. In conclusion, our data suggest that long-term, low-dose therapy with MTX does not induce osteopenia in children with JRA.

KW - Bone mass

KW - Bone mineral density

KW - Children

KW - Methotrexate

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0032869395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032869395&partnerID=8YFLogxK

U2 - 10.1007/s001980050189

DO - 10.1007/s001980050189

M3 - Article

C2 - 10501775

AN - SCOPUS:0032869395

VL - 10

SP - 20

EP - 25

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 1

ER -